SI3504214T1 - Kondenzirane triciklične piridazinonske spojine, uporabne pri zdravljenju okužb z ortomiksovirusom - Google Patents
Kondenzirane triciklične piridazinonske spojine, uporabne pri zdravljenju okužb z ortomiksovirusomInfo
- Publication number
- SI3504214T1 SI3504214T1 SI201730650T SI201730650T SI3504214T1 SI 3504214 T1 SI3504214 T1 SI 3504214T1 SI 201730650 T SI201730650 T SI 201730650T SI 201730650 T SI201730650 T SI 201730650T SI 3504214 T1 SI3504214 T1 SI 3504214T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compounds useful
- fused tricyclic
- pyridazinone compounds
- treat
- orthomyxovirus infections
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380712P | 2016-08-29 | 2016-08-29 | |
| EP17771587.7A EP3504214B1 (en) | 2016-08-29 | 2017-08-25 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| PCT/IB2017/055137 WO2018042303A1 (en) | 2016-08-29 | 2017-08-25 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3504214T1 true SI3504214T1 (sl) | 2021-04-30 |
Family
ID=59923494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730650T SI3504214T1 (sl) | 2016-08-29 | 2017-08-25 | Kondenzirane triciklične piridazinonske spojine, uporabne pri zdravljenju okužb z ortomiksovirusom |
| SI201731493T SI3848372T1 (sl) | 2016-08-29 | 2017-08-25 | Kondenzirane triciklične piridazinonske spojine, uporabne pri zdravljenju okužb z ortomiksovirusom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201731493T SI3848372T1 (sl) | 2016-08-29 | 2017-08-25 | Kondenzirane triciklične piridazinonske spojine, uporabne pri zdravljenju okužb z ortomiksovirusom |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10160764B2 (sl) |
| EP (3) | EP3504214B1 (sl) |
| JP (2) | JP7221861B2 (sl) |
| CN (2) | CN113683614A (sl) |
| AR (1) | AR109438A1 (sl) |
| CA (1) | CA3035302A1 (sl) |
| ES (2) | ES2859510T3 (sl) |
| JO (1) | JOP20170169A1 (sl) |
| MX (1) | MX2019002438A (sl) |
| PL (2) | PL3848372T3 (sl) |
| PT (2) | PT3848372T (sl) |
| SI (2) | SI3504214T1 (sl) |
| TW (2) | TW202342482A (sl) |
| UY (1) | UY37378A (sl) |
| WO (1) | WO2018042303A1 (sl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2821394T3 (es) * | 2013-09-12 | 2021-04-26 | Alios Biopharma Inc | Compuestos de 7,8-dihidro-3H-pirazino[1,2-b]piridazin-3,5(6H)-diona y usos de los mismos |
| WO2017104691A1 (ja) | 2015-12-15 | 2017-06-22 | 塩野義製薬株式会社 | キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬 |
| EP3426656B1 (en) | 2016-03-08 | 2021-05-12 | Novartis AG | Tricyclic compounds useful to treat orthomyxovirus infections |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| SG11202011447UA (en) | 2018-01-17 | 2020-12-30 | Jiangxi Caishi Pharmaceutical Technology Co Ltd | Pyridone derivative, composition and use as antiviral drug thereof |
| KR20230031990A (ko) | 2018-02-28 | 2023-03-07 | 노파르티스 아게 | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 |
| CN108440564B (zh) * | 2018-04-11 | 2019-08-06 | 安帝康（无锡）生物科技有限公司 | 被取代的多环氨基甲酰基吡啶酮衍生物及其前药 |
| US11312727B1 (en) | 2018-10-10 | 2022-04-26 | Janssen Biopharma, Inc. | Macrocyclic flu endonuclease inhibitors |
| CN115135646B (zh) * | 2019-12-23 | 2024-05-17 | 石家庄迪斯凯威医药科技有限公司 | 取代的多环化合物及其药物组合物和用途 |
| WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
| EP2181985B1 (en) | 2001-08-10 | 2011-10-26 | Shionogi & Co., Ltd. | Antiviral Agent |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| FR2901795A1 (fr) | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| US9238657B2 (en) | 2008-10-31 | 2016-01-19 | Shionogi & Co., Ltd. | Cephalosporin having catechol group |
| WO2010110231A1 (ja) | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | 置換された３－ヒドロキシ－４－ピリドン誘導体 |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| TR201808501T4 (tr) | 2009-06-15 | 2018-07-23 | Shionogi & Co | Sübstitüe polisiklik karbamoilpiridon türevi. |
| JP2013515734A (ja) | 2009-12-23 | 2013-05-09 | エラン ファーマシューティカルズ，インコーポレイテッド | ポロ様キナーゼの阻害薬としてのプテリジノン |
| US8541407B2 (en) | 2010-03-31 | 2013-09-24 | Arqule, Inc. | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| KR101773226B1 (ko) | 2010-09-24 | 2017-09-12 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 카르바모일 피리돈 유도체의 프로드러그 |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| RU2014113230A (ru) * | 2011-10-12 | 2015-11-20 | Шионоги Энд Ко., Лтд. | Полициклическое производное пиридона, обладающее ингибирующей активностью в отношении интегразы |
| EP2889287B1 (en) | 2012-09-20 | 2016-08-31 | Celltrion, Inc. | Dolastatin-10 derivative, method of producing same and anticancer drug composition containing same |
| BR112015012693A2 (pt) | 2013-01-08 | 2017-07-11 | European Molecular Biology Laboratory | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral |
| CN105636936B (zh) | 2013-08-21 | 2022-04-05 | 詹森生物制药有限公司 | 抗病毒化合物 |
| WO2015038665A1 (en) | 2013-09-11 | 2015-03-19 | University Of Southern California | A composition of stem cells having highly expressed fas ligand |
| ES2821394T3 (es) | 2013-09-12 | 2021-04-26 | Alios Biopharma Inc | Compuestos de 7,8-dihidro-3H-pirazino[1,2-b]piridazin-3,5(6H)-diona y usos de los mismos |
| EP3030549B8 (en) | 2013-09-12 | 2019-04-10 | Janssen BioPharma, Inc. | Pyridazinone compounds and uses thereof |
| EP3166951A1 (en) | 2014-07-07 | 2017-05-17 | Savira Pharmaceuticals GmbH | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| MX2017011655A (es) | 2015-03-11 | 2018-04-30 | Alios Biopharma Inc | Compuestos de aza-piridona y usos de estos. |
| EP3426656B1 (en) | 2016-03-08 | 2021-05-12 | Novartis AG | Tricyclic compounds useful to treat orthomyxovirus infections |
| WO2017156407A1 (en) | 2016-03-10 | 2017-09-14 | Alios Biopharma, Inc. | Method of preparing aza-pyridone compounds |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| CA3028751A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP2019059697A (ja) * | 2017-09-28 | 2019-04-18 | 塩野義製薬株式会社 | 置換された多環性ピリダジン誘導体およびそのプロドラッグ |
| CN110041327B (zh) | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| SG11202011447UA (en) | 2018-01-17 | 2020-12-30 | Jiangxi Caishi Pharmaceutical Technology Co Ltd | Pyridone derivative, composition and use as antiviral drug thereof |
| US10899717B2 (en) | 2018-02-28 | 2021-01-26 | Japan Tobacco Inc. | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof |
| KR20230031990A (ko) | 2018-02-28 | 2023-03-07 | 노파르티스 아게 | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 |
| MX2020008746A (es) | 2018-02-28 | 2020-09-28 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. |
| AR123121A1 (es) | 2018-02-28 | 2022-11-02 | Japan Tobacco Inc | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillo saturado y su uso farmacéutico |
-
2016
- 2016-08-29 JO JOP/2017/0169A patent/JOP20170169A1/ar unknown
-
2017
- 2017-08-25 ES ES17771587T patent/ES2859510T3/es active Active
- 2017-08-25 EP EP17771587.7A patent/EP3504214B1/en active Active
- 2017-08-25 SI SI201730650T patent/SI3504214T1/sl unknown
- 2017-08-25 US US15/686,652 patent/US10160764B2/en active Active
- 2017-08-25 EP EP20210329.7A patent/EP3848372B1/en active Active
- 2017-08-25 PL PL20210329.7T patent/PL3848372T3/pl unknown
- 2017-08-25 SI SI201731493T patent/SI3848372T1/sl unknown
- 2017-08-25 CN CN202110956692.7A patent/CN113683614A/zh active Pending
- 2017-08-25 US US16/328,616 patent/US11098051B2/en active Active
- 2017-08-25 ES ES20210329T patent/ES2974494T3/es active Active
- 2017-08-25 PT PT202103297T patent/PT3848372T/pt unknown
- 2017-08-25 EP EP23217305.4A patent/EP4356969A3/en active Pending
- 2017-08-25 JP JP2019511749A patent/JP7221861B2/ja active Active
- 2017-08-25 MX MX2019002438A patent/MX2019002438A/es unknown
- 2017-08-25 CN CN201780065653.XA patent/CN109863151B/zh active Active
- 2017-08-25 PL PL17771587T patent/PL3504214T3/pl unknown
- 2017-08-25 WO PCT/IB2017/055137 patent/WO2018042303A1/en unknown
- 2017-08-25 CA CA3035302A patent/CA3035302A1/en active Pending
- 2017-08-25 PT PT177715877T patent/PT3504214T/pt unknown
- 2017-08-28 TW TW112101158A patent/TW202342482A/zh unknown
- 2017-08-28 TW TW106129086A patent/TWI803467B/zh active
- 2017-08-28 UY UY0001037378A patent/UY37378A/es unknown
- 2017-08-29 AR ARP170102385A patent/AR109438A1/es unknown
-
2021
- 2021-07-13 US US17/374,237 patent/US11912715B2/en active Active
-
2022
- 2022-11-22 JP JP2022186394A patent/JP2023027102A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3848372T1 (sl) | Kondenzirane triciklične piridazinonske spojine, uporabne pri zdravljenju okužb z ortomiksovirusom | |
| IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| HK1244276A1 (zh) | 用於治療hiv的稠合嘧啶化合物 | |
| PL3178817T3 (pl) | Postać amorficzna związku tetracyklicznego | |
| EP3303341A4 (en) | Fused tricyclic heterocyclic compounds useful for treating hiv infection | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| IL254424A0 (en) | Disubstituted heterocyclic tricyclic compounds | |
| HK1251465A1 (zh) | 包含三環雜環化合物的組合物 | |
| SI3535257T1 (sl) | Proces za čiščenje prirazolpiridazinov | |
| SG11201702274RA (en) | Process for purification of organic composition | |
| IL249907A0 (en) | Tricyclic substances containing a triazole ring | |
| IL260094A (en) | Treatment of hand eczema | |
| GB201409161D0 (en) | Routing scheme switching | |
| IL248838A0 (en) | Compressed heteroaromatic spirocyclic compounds for the treatment of bacterial infections | |
| GB201404848D0 (en) | Pathogenic infections | |
| ZA201801775B (en) | Soap bar having separate concentrated regions of specifically selected components | |
| PL3494122T3 (pl) | Podstawione rybonukleozydy heteropentadienopirolopirymidynowe do użytku terapeutycznego | |
| ZA201700710B (en) | Pathogenic control of apoptosis | |
| PL3131890T3 (pl) | Związki do leczenia zakażeń wirusowych | |
| GB201510870D0 (en) | Treatment of infarction | |
| ZA201902183B (en) | Purification process of fviii | |
| ZA201804025B (en) | Inactivation of viruses by delipidation | |
| GB201619704D0 (en) | Treatment of pathogenic infections | |
| GB201512635D0 (en) | Uses of therapeutic compounds | |
| PL3137475T3 (pl) | Oczyszczanie epidaunorubicyny |